Gland Pharma Limited (GLAND.BO)
INR 1762.35
(-0.09%)
INR 1762.35
(-0.09%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 11.08 Billion | 3.63 Billion | 7.9 Billion | 6.04 Billion | 7 Billion | 1.85 Billion |
| Net Income | 7.72 Billion | 10.54 Billion | 16.18 Billion | 13.34 Billion | 9.92 Billion | 6.86 Billion |
| Depreciation & Amortization | 3.44 Billion | 1.46 Billion | 1.1 Billion | 987.8 Million | 945.87 Million | 821.2 Million |
| Deferred income taxes | - | - | -4.14 Billion | -3.25 Billion | -2.77 Billion | - |
| Stock-based compensation | - | - | 46.21 Million | 155.34 Million | 164.84 Million | - |
| Change in working capital | -531.99 Million | -4.17 Billion | -3.93 Billion | -4.35 Billion | -799.42 Million | -3.53 Billion |
| Other non-cash items | 7.71 Billion | -4.19 Billion | -1.35 Billion | -830.38 Million | -452.35 Million | -2.29 Billion |
| Investing Cash Flow | -18.93 Billion | 12.08 Billion | -10.02 Billion | -15.24 Billion | -7.66 Billion | -3.14 Billion |
| Investments in PPE | -3.98 Billion | -2.23 Billion | -5.22 Billion | -2.28 Billion | -1.94 Billion | -1.35 Billion |
| Acquisitions | -10.2 Billion | 1.4 Million | 3.99 Million | 4.3 Million | 238.86 Million | 5.45 Million |
| Investment purchases | -7.4 Billion | -4.69 Billion | -16.81 Billion | -13.57 Billion | -6.38 Billion | -2.18 Billion |
| Sales/Maturities of investments | 2.65 Billion | 17.4 Billion | 10.7 Billion | - | - | - |
| Other Investing Activities | 1.29 Billion | 1.6 Billion | 1.3 Billion | 619.37 Million | 434.47 Million | 398.05 Million |
| Financing Cash Flow | -7.73 Billion | 149.19 Million | 348.98 Million | 12.38 Billion | -68.71 Million | -31.24 Million |
| Debt repayment | -7.56 Billion | -1.12 Million | -1.36 Million | -8.91 Million | -5.3 Million | -4.25 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 5.26 Million | 214.96 Million | 385.52 Million | 12.41 Billion | - | - |
| Other Financing Activities | -436.64 Million | -64.65 Million | -35.18 Million | -24.56 Million | -63.41 Million | -26.99 Million |
| Accounts receivables | -3.24 Billion | 1.44 Billion | -5.27 Billion | -602.01 Million | -805.17 Million | -458.96 Million |
| Accounts payables | -3.78 Billion | 1.2 Billion | 658.46 Million | 1.42 Billion | -2.14 Billion | 1.13 Billion |
| Inventory | 6.66 Billion | -7.59 Billion | 895.01 Million | -5.18 Billion | 1.55 Billion | -3.99 Billion |
| Other working capital | -154.51 Million | 763.91 Million | -212.05 Million | 5.14 Million | 596.51 Million | -220.15 Million |
| Cash at beginning of period | 19.08 Billion | 3.18 Billion | 4.92 Billion | 1.69 Billion | 2.36 Billion | 3.72 Billion |
| Cash at end of period | 18.39 Billion | 19.08 Billion | 3.18 Billion | 4.92 Billion | 1.69 Billion | 2.36 Billion |
| Capital Expenditure | -3.98 Billion | -2.23 Billion | -5.22 Billion | -2.28 Billion | -1.94 Billion | -1.35 Billion |
| Effect of forex changes on cash | 77.23 Million | 30 Million | 33.11 Million | 35.77 Million | 51.09 Million | -44.31 Million |
| Net cash flow / Change in cash | -694.63 Million | 15.9 Billion | -1.73 Billion | 3.22 Billion | -669.05 Million | -1.36 Billion |
| Free Cash Flow | 7.09 Billion | 1.4 Billion | 2.68 Billion | 3.76 Billion | 5.06 Billion | 495.11 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 7.72 Billion | 1.91 Billion | 1.94 Billion | 1.94 Billion | 10.54 Billion | 786.83 Million |
| Depreciation & Amortization | 3.44 Billion | 1.05 Billion | 813 Million | 653.15 Million | 1.46 Billion | 375.42 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -531.99 Million | - | - | - | -4.17 Billion | - |
| Other non-cash items | 7.71 Billion | -865.13 Million | -813 Million | -653.15 Million | -4.19 Billion | -375.42 Million |
| Investing Cash Flow | -18.93 Billion | - | - | - | 12.08 Billion | - |
| Investments in PPE | -3.98 Billion | - | - | - | -2.23 Billion | - |
| Acquisitions | -10.2 Billion | - | - | - | 1.4 Million | - |
| Investment purchases | -7.4 Billion | - | - | - | -4.69 Billion | - |
| Sales/Maturities of investments | 2.65 Billion | - | - | - | 17.4 Billion | - |
| Other Investing Activities | - | - | - | - | 1.6 Billion | - |
| Financing Cash Flow | -7.73 Billion | - | - | - | 149.19 Million | - |
| Debt repayment | -7.56 Billion | - | - | - | -1.12 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 5.26 Million | - | - | - | 214.96 Million | - |
| Other Financing Activities | - | - | - | - | -64.65 Million | - |
| Accounts receivables | -3.24 Billion | - | - | - | 1.44 Billion | - |
| Accounts payables | -3.78 Billion | - | - | - | 1.2 Billion | - |
| Inventory | 6.66 Billion | - | - | - | -7.59 Billion | - |
| Other working capital | -154.51 Million | - | - | - | 763.91 Million | - |
| Cash at beginning of period | 19.08 Billion | 4.8 Billion | 2.86 Billion | 19.08 Billion | 3.18 Billion | 18.3 Billion |
| Cash at end of period | 18.39 Billion | 6.91 Billion | 4.8 Billion | 1.94 Billion | 19.08 Billion | 19.08 Billion |
| Capital Expenditure | -3.98 Billion | - | - | - | -2.23 Billion | - |
| Effect of forex changes on cash | 77.23 Million | - | - | - | 30 Million | - |
| Net cash flow / Change in cash | -694.63 Million | 2.1 Billion | 1.94 Billion | -17.14 Billion | 15.9 Billion | 786.83 Million |
| Free Cash Flow | 7.09 Billion | 2.1 Billion | 1.94 Billion | 1.94 Billion | 1.4 Billion | 786.83 Million |
5076
CONCORDBIO
KWI
HBMN
OCGPF
LTF